Holzle E, Plewig G, von Kries R, et al. Polymorphous light eruption. J Invest Dermatol. 1987;88(3 Suppl):32s-38s.
Dummer R, Ivanova K, Scheidegger EP, et al. Clinical and therapeutic aspects of polymorphous light eruption. Dermatology. 2003;207:93-95.
Lehmann P. Diagnostic approach to photodermatoses. J Dtsch Dermatol Ges. 2006;4:965-975.
Ortel B, Tanew A, Honigsmann H, et al. Polymorphous light eruption. Action spectrum and photoprotection. J Am Acad Dermatol. 1986;14:748-753.
Murphy GM, Logan RA, Lovell CR, et al. Prophylactic PUVA and UVB therapy in polymorphic light eruption - a controlled trial. Br J Dermatol. 1987;116:531-538.
1. Holzle E, Plewig G, von Kries R, et al. Polymorphous light eruption. J Invest Dermatol. 1987;88(3 Suppl):32s-38s.
2. Kontos AP, Cusack CA, Chaffins M, et al. Polymorphous light eruption in African Americans: pinpoint papular variant. Photodermatol Photoimmunol Photomed. 2002;18:303-306.
3. Bansal I, Kerr H, Janiga JJ, et al. Pinpoint papular variant of polymorphous light eruption: clinical and pathological. Eur Acad Dermatol Venereol. 2006;20:406-410.
4. Calzavara Pinton PG, Venturini M, Capezzera R, et al. Photosensitive erythema multiforme and erythema multiforme-like polymorphous light eruption. Photodermatol Photoimmunol Photomed. 2003;19:157-159.
5. Elpern DJ, Morison WL, Hood AF. Papulovesicular light eruption. A defined subset of polymorphous light eruption. Arch Dermatol. 1985;121:1286-1288.
6. Diepgen TL, Haberle M, Fartasch M, et al. Characteristics of polymorphous light dermatosis - results of a prospective survey and study of 302 affected patients. Z Hautkr. 1989:15;64:279-280, 283-285.
7. Neumann NJ, Holzle E, Lehmann P. Polymorphous light dermatoses. J Dtsch Dermatol Ges. 2004;2:220-224, 226.
8. Guarrera M, Micalizzi C, Rebora A. Heterogeneity of polymorphous light eruption: a study of 105 patients. Arch Dermatol. 1993;129:1060-1061.
9. Berg M. Epidemiological studies of the influence of sunlight on the skin. Photodermatology. 1989;6:80-84.
10. Dummer R, Ivanova K, Scheidegger EP, et al. Clinical and therapeutic aspects of polymorphous light eruption. Dermatology. 2003;207:93-95.
11. Jansen CT. The natural history of polymorphous light eruptions. Arch Dermatol. 1979;115:165-169.
12. Stratigos AJ, Antoniou C, Papadakis P, et al. Juvenile spring eruption: clinicopathologic features and phototesting results in 4 cases. J Am Acad Dermatol. 2004;50(suppl 2):S57-S60.
13. Lava SA, Simonetti GD, Ragazzi M,et al. Juvenile spring eruption: an outbreak report and systematic review of the literature. Br J Dermatol. 2013;168:1066-1072.
14. Balasubramanian P, Jagadeesan S, Sekar L, et al. An interesting observation of polymorphous light eruption occurring on hypopigmented scars. Indian Dermatol Online J. 2015;6:294-296.
15. Morison WL, Stern RS. Polymorphous light eruption: a common reaction uncommonly recognized. Acta Derm Venereol. 1982;62:237-240.
16. Fotiades J, Soter NA, Lim HW. Results of evaluation of 203 patients for photosensitivity in a 7.3-year period. J Am Acad Dermatol. 1995;33:597-602.
17. Kerr HA, Lim HW. Photodermatoses in African Americans: a retrospective analysis of 135 patients over a 7-year period. J Am Acad Dermatol. 2007;57:638-643.
18. Aubin F. Why is polymorphous light eruption so common in young women? Arch Dermatol Res. 2004;296:240-241.
19. Millard TP, Bataille V, Snieder H, et al. The heritability of polymorphic light eruption. J Invest Dermatol. 2000;115:467-470.
20. McGregor JM, Grabczynska S, Vaughan R, et al. Genetic modeling of abnormal photosensitivity in families with polymorphic light eruption and actinic prurigo. J Invest Dermatol. 2000;115:471-476.
21. Nakamura M, Henderson M, Jacobsen G, et al. Comparison of photodermatoses in African-Americans and Caucasians: a follow-up study. Photodermatol Photoimmunol Photomed. 2014;30:231-236.
22. Ros AM, Wennersten G. Current aspects of polymorphous light eruptions in Sweden. Photodermatology. 1986;3:298-302.
23. Pao C, Norris PG, Corbett M, et al. Polymorphic light eruption: prevalence in Australia and England. Br J Dermatol. 1994;130:62-64.
24. Kölgen W, Van Weelden H, Den Hengst S, et al. CD11b+ cells and ultraviolet-B-resistant CD1a+ cells in skin of patients with polymorphous light eruption. J Invest Dermatol. 1999;113:4-10.
25. Lehmann P. Diagnostic approach to photodermatoses. J Dtsch Dermatol Ges. 2006;4:965-975.
26. Ortel B, Tanew A, Honigsmann H, et al. Polymorphous light eruption. Action spectrum and photoprotection. J Am Acad Dermatol. 1986;14:748-753.
27. van de Pas CB, Hawk JL, Young AR, et al. An optimal method for experimental provocation of polymorphic light eruption. Arch Dermatol. 2004;140:286-292.
28. Salomon N, Messer G, Dick D, et al. Phototesting for polymorphic light eruption (PLE) with consecutive UVA1/UVB-irradiation. Photodermatol Photoimmunol Photomed. 1997;13:72-74.
29. Grether-Beck S, Schmitt H, Grewe M, et al. The balance between expression of transcription factor AP2 and its alternative splice product AP2B controls ultraviolet A radiation (UV AR)-induced ICAM-1 expression in human cells. Abstracts for the 27th annual meeting of the European Society for Dermatological Research: no. 112. J Invest Dermatol. 1997;109:422.
30. Grether-Beck S, Budde MA, Schmidt-Brenden H, et al. Lack of AP2B expression in lesional skin of patients with polymorphous light eruption. Allergo J. 2000;9:42.
31. Hadshiew I, Stab F, Untiedt S, et al. Effects of topically applied antioxidants in experimentally provoked polymorphous light eruption. Dermatology. 1997;195:362-368.
32. Norris PG, Morris J, McGibbon DM, et al. Polymorphic light eruption: an immunopathological study of evolving lesions. Br J Dermatol. 1989;120:173-183.
33. Schweintzger N, Gruber-Wackernagel A, Reginato E, et al. Levels and function of regulatory T cells in patients with polymorphic light eruption: relation to photohardening. Br J Dermatol. 2015;173:519-526.
34. Schweintzger NA, Gruber-Wackernagel A, Shirsath N, et al. Influence of the season on vitamin D levels and regulatory T cells in patients with polymorphic light eruption. Photochem Photobiol Sci. 2016;15:440-446.
35. Reddy H, Carmichael AJ, Wahie S. Severity of polymorphic light eruption in pre- and post-menopausal women: a comparative study. J Eur Acad Dermatol Venereol. 2015;29:97-101.
36. Hiramoto K, Tanaka H, Yanagihara N, et al. Effect of 17beta-estradiol on immunosuppression induced by ultraviolet B irradiation. Arch Dermatol Res. 2004;295:307-311.
37. Creamer D, McGregor JM, Hawk JL. Polymorphic light eruption occurring in common variable hypogammaglobulinaemia, and resolving with intravenous immunoglobulin therapy. Clin Exp Dermatol. 1999;24:273-274.
38. Holzle E, Plewig G, Hofmann C, et al. Polymorphous light eruption. Experimental reproduction of skin lesions. J Am Acad Dermatol. 1982;7:111-125.
39. Jansen CT. Erythemal and pigmentary phototest reactions in polymorphic light eruptions. Acta Derm Venereol. 1979;59:499-503.
40. Norris P, Bacon K, Bird C, et al. The role of interleukins 1, 6 and 8 as lymphocyte attractants in the photodermatoses polymorphic light eruption and chronic actinic dermatitis. Clin Exp Dermatol. 1999;24:321-326.
41. Norris P, Poston RN, Thomas DS, et al. The expression of endothelial leukocyte adhesion molecule-1 (ELAM-1), intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) in experimental cutaneous inflammation: a comparison of ultraviolet B erythema and delayed hypersensitivity. J Invest Dermatol. 1991;96:763-770.
42. Krutmann J, Grewe M. Involvement of cytokines, DNA damage, and reactive oxygen intermediates in ultraviolet radiation-induced modulation of intercellular adhesion molecule-1 expression. J Invest Dermatol. 1995;105(1 Suppl):67s-70s.
43. Grether-Beck S, Olaizola-Horn S, Schmitt H, et al. Activation of transcription factor AP-2 mediates UVA radiation- and singlet oxygen-induced expression of the human intercellular adhesion molecule 1 gene. Proc Natl Acad Sci U S A. 1996;93:14586-14591.
44. Hadshiew IM, Treder-Conrad C, v. Bülow R, et al. Polymorphous light eruption (PLE) and a new potent antioxidant and UVA-protective formulation as prophylaxis. Photodermatol Photoimmunol Photomed. 2004;20:200-204.
45. Hood AF, Elpern DJ, Morison EL. Histopathologic findings in papulovesicular light eruption. J Cutan Pathol. 1986;13:13-21.
46. Hawk JL, Magnus IA. Chronic actinic dermatitis - an idiopathic photosensitivity syndrome including actinic reticuloid and photosensitive eczema. Br J Dermatol. 1979;101:24.
47. Norris PG, Hawk JL. Chronic actinic dermatitis. A unifying concept. Arch Dermatol. 1990;126:376-378.
48. Wolf C, Honigsmann H. The syndrome of chronic actinic dermatitis. Persistent light reaction - actinic reticuloid. Hautarzt. 1988;39:635-641.
49. Ryckaert S, Roelandts R. Solar urticaria: a report of 25 cases and difficulties in phototesting. Arch Dermatol. 1998;134:71-74.
50. Norris DA. Pathomechanisms of photosensitive lupus erythematosus. J Invest Dermatol. 1993;100:58s-68s.
51. Fisher DA, Epstein JH, Kay DN, et al. Polymorphous light eruption and lupus erythematosus. Differential diagnosis by fluorescent microscopy. Arch Dermatol. 1970;101:458-461.
52. Alves JV, António AM, Matos D, et al. Fixed eruption induced by sunlight. J Dtsch Dermatol Ges. 2015;13:578-579.
53. Valdeolivas-Casillas N, Piteiro-Bermejo AB, Trasobares-Marugán L, et al. Fixed sunlight eruption: a case report. J Eur Acad Dermatol Venereol. 2015;30:894-895.
54. Valdivieso R, Cañarte C. It is not a fixed drug eruption, it is a fixed "sunlight" eruption. Int J Dermatol. 2010;49:1421-1423.
55. Winkelmann RR, Del Rosso J, Rigel DS. Polypodium leucotomos extract: a status report on clinical efficacy and safety. J Drugs Dermatol. 2015;14:254-261.
56. Przybilla B, Heppeler M, Ruzicka T. Preventive effect of an E. coli-filtrate (Colibiogen) in polymorphous light eruption. Br J Dermatol. 1989;121:229-233.
57. Rhodes L, Durham B, Fraser W, et al. Dietary fish oil reduces basal and ultraviolet B-generated PGE2 levels in skin. J Invest Dermatol. 1995;105:532-535.
58. Marini A, Jaenicke T, Grether-Beck S, et al. Prevention of polymorphic light eruption by oral administration of a nutritional supplement containing lycopene, β-carotene, and Lactobacillus johnsonii: results from a randomized, placebo-controlled, double-blinded study. Photodermatol Photoimmunol Photomed. 2014;30:189-194.
59. Norris PG, Hawk JL. Successful treatment of severe polymorphous light eruption with azathioprine. Arch Dermatol. 1989;125:1377-1379.
60. National Institute for Health and Care Excellence (NICE). Sunlight exposure: risks and benefits. February 2016. https://www.nice.org.uk/ (last accessed 30 August 2017).
61. Gies HP, Roy CR, Elliott G, et al. Ultraviolet radiation protection factors for clothing. Health Phys. 1994;67:131-139.
62. Diffey BL, Farr PM. Sunscreen protection against UVB, UVA and blue light: an in vivo and in vitro comparison. Br J Dermatol. 1991;124:258-263.
63. McFadden N. UVA sensitivity and topical photoprotection in polymorphous light eruption. Photodermatol. 1984;1:76-78.
64. Murphy GM, Logan RA, Lovell CR, et al. Prophylactic PUVA and UVB therapy in polymorphic light eruption - a controlled trial. Br J Dermatol. 1987;116:531-538.
65. Bilsland D, George SA, Gibbs NK, et al. A comparison of narrow band phototherapy (TL-01) and photochemotherapy (PUVA) in the management of polymorphic light eruption. Br J Dermatol. 1993;129:708-712.
66. Berg M, Ros AM, Berne B. Ultraviolet A phototherapy and trimethylpsoralen UVA photochemotherapy in polymorphous light eruption - a controlled study. Photodermatol Photoimmunol Photomed. 1994;10:139-143.
67. Corbett, MF, Hawk JL, Herxheimer A, et al. Controlled therapeutic trials in polymorphous light eruption. Br J Dermatol. 1982;107:571-581.
68. Morison WL, Marwaha S, Beck L. PUVA-induced phototoxicity: incidence and causes. J Am Acad Dermatol. 1997;36:183-185.
69. Menage P du H, Norris P, Cheong W, et al. Short course PUVA therapy is effective in polymorphic light eruption. Br J Dermatol. 1992;127:32.
70. Palmer RA, Friedmann PS. A comparison of six and 12 PUVA treatments in the prohylaxis of polymorphic light eruption. Clin Exp Dermatol. 2004;29:141-143.
71. Stern RS, Vakeva LH. Noncutaneous malignant tumors in the PUVA follow-up study: 1975-1996. J Invest Dermatol. 1997;108:897-900.
72. Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol. 2001;44:755-761.
73. Lindelof B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer: a large-scale epidemiological study. Lancet. 1991;338:91-93.
74. Ling TC, Clayton TH, Crawley J, et al. British Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of psoralen-ultraviolet A therapy 2015. Br J Dermatol. 2016;174:24-55.
75. Eberlein-Konig B, Fesq H, Abeck D, et al. Systemic vitamin C and vitamin E do not prevent photoprovocation test reactions in polymorphous light eruption. Photodermatol Photoimmunol Photomed. 2000;16:50-52.
76. Jansen CT. Oral carotenoid treatment in polymorphous light eruption: a cross-over comparison with oxychloroquine and placebo. Photodermatol. 1985;2:166-169.
77. Haberle MM, Arnold HU, Koch E, et al. Nikotinsäureamid zur Prophylaxe der polymorphen Lichtdermatose (PLD) - eine plazebokontrollierte Doppelblindstudie. Vita Min Spur. 1991;6:29-37.
78. Shipley DR, Hewitt JB. Polymorphic light eruption treated with cyclosporin. Br J Dermatol. 2001;144:446-447.
79. Murphy GM, Hawk JL, Magnus IA. Hydroxychloroquine in polymorphic light eruption: a controlled trial with drug and visual sensitivity monitoring. Br J Dermatol. 1987;116:379-386.
80. Pareek A, Khopkar U, Sacchidanand S, et al. Comparative study of efficacy and safety of hydroxychloroquine and chloroquine in polymorphic light eruption: a randomized, double-blind, multicentric study. Indian J Dermatol Venereol Leprol. 2008;74:18-22.
81. Saul A, Flores O, Novales J. Polymorphous light eruption: treatment with thalidomide. Australas J Dermatol. 1976;17:17-21.
82. Kerscher M, Przybilla B, Rueff F. Successful preventive treatment of polymorphous light eruption with an E. coli-filtrate. Allergo J. 1998;7:261-263.
使用此内容应接受我们的免责声明。
BMJ临床实践的持续改进离不开您的帮助和反馈。如果您发现任何功能问题和内容错误,或您对BMJ临床实践有任何疑问或建议,请您扫描右侧二维码并根据页面指导填写您的反馈和联系信息*。一旦您的建议在我们核实后被采纳,您将会收到一份小礼品。
如果您有紧急问题需要我们帮助,请您联系我们。
邮箱:bmjchina.support@bmj.com
电话:+86 10 64100686-612
*您的联系信息仅会用于我们与您确认反馈信息和礼品事宜。
BMJ临床实践官方反馈平台